Enabling Immunotherapy

Choon has extensive experience in financial management and marketing in small and large international organizations, including as a start-up CEO.

Alessandra is a tumor immunologist with international experience in various aspects of translational immunology and business development, in academic and industry settings.

Michael is an immunologist with in-depth and hands-on expertise in mass cytometry and multiplexing tetramer technology in the fields of infectious diseases and cancer.

Matt is an experienced life science business development executive and an entrepreneur.

Choon has extensive experience in financial management and marketing in small and large international organizations, including as a start-up CEO.

Evan pioneered the use of mass cytometry for high-dimensional immune profiling in Stanford and A*STAR; his research focus is T cell immunology and over the years has developed combinatorial tetramer coding solutions and many analytical tools. He is currently Principal Investigator at the Vaccine and Infectious Disease Division of Fred Hutch.

Alessandra is a tumor immunologist with international experience in various aspects of translational immunology and business development, in academic and industry settings.

Nori is a partner at University of Tokyo Edge Capital (UTEC), where he manages investment focused on physical science and advanced technology.

Evan pioneered the use of mass cytometry for high-dimensional immune profiling in Stanford and A*STAR; his research focus is T cell immunology and over the years has developed combinatorial tetramer coding solutions and many analytical tools. He is currently Principal Investigator at the Vaccine and Infectious Disease Division of Fred Hutch.

Mr Jack Ball was Chief Commercial Officer of Accuri Cytometers. Mr. Ball has a long and proven record for bringing life science products to market and capitalizing on existing product potential. He was CEO of Amnis Corporation, a venture backed technology start-up developing high-end imaging flow cytometers. He has also served as CCO for Molecular Probes, Inc., the world leader in reagents for cell analysis, including flow cytometry consumables. Prior to that he was with Orchid Biosciences as Sr. VP and General Manager with Amersham Pharmacia Biotech Inc., where he rose to President, Region North America and was responsible for sales, marketing, and customer support for all products sold in North America

Dr. Graeme Martin is President of Takeda Ventures Inc., the venture investment arm of Takeda Pharmaceutical Company, Ltd. He has overseen investment in 26 early-stage companies of strategic importance to Takeda. During more than 35 years in multinational pharmaceutical and biotech companies in Europe and the United States, Dr. Martin has worked on three IND candidates, including Zomig®, now marketed worldwide for migraine management. He is the author of more than 85 peer-reviewed publications and book chapters, and received his bachelor of science degree in pharmacology from the University of Bath, UK and his doctorate from University College, London, UK.

Andreas was previously Global Head of Clinical Research & Exploratory Development in Roche, more recently at the University of Basel and on the Board of several biotech companies.

Prof Soo was founding Director of National Cancer Centre Singapore and key contributor in the establishment of Duke-NUS School of Medicine. He is a renowned cancer clinician and has been critical in placing Singapore to the forefront of translational medicine.

Mr. Juan Harrison is a biotechnology and pharmaceutical executive focused on company
formation, strategy, partnering, venture investment and licensing transactions. He is currently
providing advisory services to several early stage companies, venture capital enterprises and
academic centers. He was previously Vice President and Head of Strategic Academic Alliances
at Takeda Pharmaceuticals where he was responsible for establishing several broad drug
discovery alliances, including the Tri-Institutional Therapeutics Discovery Institute (Weill Cornell
Medicine, Rockefeller University and Memorial Sloan Kettering Cancer Center), the Alliance for
Innovative Medicines (Stanford University), the Seattle Partnership for Research in Innovative
Therapeutics (SPRInT, including the Fred Hutchinson Cancer Research Center, the University of
Washington, and Seattle Children’s Hospital), and the Dana Farber Cancer Institute. Before
leading Takeda’s SAA, he was VP at Takeda Ventures where he invested in several companies
including Envoy Therapeutics, later acquired by Takeda. Mr. Harrison has been working in the
biopharmaceutical industry since 1985 and has held senior positions in Alza Pharmaceuticals,
Connetics, PowderJect and XenoPort. He received a BS in Combined Science from Santa Clara
University with emphasis in Chemistry and Biochemistry.

Based in Ann Arbor, Michigan, John Freshley is a high-energy entrepreneur, company builder
and leader with 20+ years experience in a variety of healthcare-focused companies. He has
founded, launched, and/or led 8 early stage life science companies, including Compendia
Bioscience through its acquisition by Life Technologies (now Thermo Fisher).

Craig has a Ph.D. in Biochemistry with over 30 years of work experience managing the development of new product pipelines, intellectual property portfolios and has significant licensing as well as acquisition diligence experience.  His expertise spans the technology disciplines of protein, cell and molecular biology for the Life Science Reagents, Drug Discovery and Biopharmaceutical Manufacturing markets.   He has worked for both small privately held startups as well as large multinational publicly traded companies. He is currently running his own consulting business focusing on startups with novel technology.